Multiple Sclerosis Studies

If you think you may qualify for one of these studies, please contact CNI’s Research Department at 303-806-7423.

A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis. (EXPAND)
eligibility and information (clinicaltrials.gov) – Closed to Enrollment
additional information
Principal Investigator: Allen C. Bowling, MD, PhD
Sub-Investigator: Karen O. Theriot, MD

A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients: To describe efficacy, tolerability and convenience of teriflunomide treatment through the evaluation of Patient Reported Outcomes
eligibility and information – Closed to Enrollment
Principal Investigator: Allen C. Bowling, MD, PhD
Sub-Investigator: Karen O. Theriot, MD

A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (dimethyl fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate (RESPOND)
Principal Investigator: Allen C. Bowling, MD, PhD
Closed to Enrollment

Colorado Neurological Insitute